Muscular Atrophy, Spinal
Conditions
Brief summary
This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Interventions
DRUGRisdiplam
Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 19 Days
Healthy volunteers
No
Inclusion criteria
* Male or female newborn infant aged \<20 days at first dose * Newborn infants with genetic diagnosis of 5q-autosomal recessive SMA or newborn infants identified as positive for SMA via newborn screening or via prenatal testing. * Gestational age equal to or greater than 37 weeks * Receiving adequate nutrition and hydration at the time of screening * Adequately recovered from any acute illness at baseline and considered well enough to participate in the study * Parent/caregiver is willing to consider nasogastric, nasojejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator.
Exclusion criteria
* Presence of clinical symptoms or signs consistent with SMA Type 0 * In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures * Systolic blood pressure or diastolic blood pressure or heart rate abnormalities * Presence of clinically relevant electrocardiogram (ECG) abnormalities * The infant (or the person breastfeeding the infant) taking any of the following: any inhibitor of CYP3A4 taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing, any inducer of CYP3A4 taken within 4 weeks (or within 5 times the elimination half-life, whichever is longer prior to dosing, and/or use of any multidrug and toxin extrusion (MATE) substrates taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing * Concurrent or previous administration of nusinersen or onasemnogene abeparvovec * Clinically significant abnormalities in laboratory test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Concentrations of Risdiplam | From Day 1 through Day 28 |
| Area Under the Plasma Concentration-Time Curve (AUC) of Risdiplam | From Day 1 through Day 28 |
| Steady-state Concentration (Css) of Risdiplam | From Day 1 through Day 28 |
| Risdiplam Free Fraction | From Day 1 through Day 28 |
| Percentage of Participants With Adverse Events | Up to 30 days after the final dose of study treatment (up to 58 days) |
| Percentage of Participants With Serious Adverse Events | Up to 30 days after the final dose of study treatment (up to 58 days) |
| Percentage of Participants With Treatment Discontinuation due to Adverse Events | Up to 30 days after the final dose of study treatment (up to 58 days) |
Countries
Belgium, Canada, Germany, Italy, Netherlands, Norway, Poland, United States
Contacts
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed